Effectiveness of Ceftazidime/Avibactam treatment for infections caused by Klebsiella pneumoniae Carbapenemase (KPC), a 30-day mortality perspective. Comparison of results with control groups treated with other antibiotics
DOI:
https://doi.org/10.12775/JEHS.2024.71.49182Keywords
Klebsiella pneumoniae Carbapenemase, ceftazidime/avibactam, 30-day mortality, infections, cohort studyAbstract
Introduction: Infections caused by Klebsiella pneumoniae carbapenemase (KPC) pose a significant clinical challenge due to increasing antibiotic resistance. This study analyzes the effectiveness of ceftazidime/avibactam treatment for KPC infections, focusing on 30-day mortality and comparing results with control groups treated with different antibiotics.
Material and methods: We conducted a retrospective analysis of six cohort studies, comparing thirty-day mortality in patients treated with ceftazidime/avibactam with control groups using other antibiotics. The studies included patients infected with KPC, and the analysis focused on therapeutic effectiveness.
Aim of the study: The aim of the study is to compare the results in terms of 30-day mortality in groups treated with ceftazidime/avibactam compared to control groups using different antibiotics. Conclusions: Data analysis from various studies revealed varied 30-day mortality outcomes in groups treated with ceftazidime/avibactam compared to control groups using different antibiotics. Ceftazidime/avibactam proved to be more effective in all studies, reducing mortality rates compared to other treatment regimens. We emphasize that emerging antibiotic resistance, especially in the case of KPC, requires a comprehensive therapeutic approach. Despite promising ceftazidime/avibactam results, factors such as overall patient health and treatment delays may influence final therapy outcomes. We also highlight controversies regarding combination therapy vs. monotherapy, necessitating further research. Our work underscores the importance of monitoring the effectiveness of KPC infection treatment and exploring new therapeutic strategies. Further clinical studies are essential to develop a fuller understanding and optimal therapeutic protocols in the face of the growing antibiotic resistance problem.References
Ashurst JV, Dawson A. Klebsiella Pneumonia. [Updated 2023 Jul 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519004/
Bagley, S. T. (1985). Habitat association of Klebsiella species. In Infection Control (Vol. 6, Issue 2). https://doi.org/10.1017/S0195941700062603
Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines-Woodhouse, G., Kashef Hamadani, B. H., Kumaran, E. A. P., McManigal, B., … Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325). https://doi.org/10.1016/S0140-6736(21)02724-0
Ding L, Shi Q, Han R, Yin D, Wu S, Yang Y, Guo Y, Zhu D, Hu F. Comparison of Four Carbapenemase Detection Methods for blaKPC-2 Variants. Microbiol Spectr. 2021 Dec 22;9(3):e0095421. doi: 10.1128/Spectrum.00954-21. Epub 2021 Dec 22. PMID: 34935416; PMCID: PMC8693920.
Zhou, Y., Wu, C., Wang, B., Xu, Y. L., Zhao, H., Guo, Y., Wu, X., Yu, J., Rao, L., Wang, X., & Yu, F. (2023). Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae. Drug Resistance Updates, 67. https://doi.org/10.1016/j.drup.2023.100918
Yang, Y., Yan, Y. H., Schofield, C. J., McNally, A., Zong, Z., & Li, G. B. (2023). Metallo-β-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery. In Trends in Microbiology (Vol. 31, Issue 7). https://doi.org/10.1016/j.tim.2023.01.013
Yahav, D., Giske, C. G., Gramatniece, A., Abodakpi, H., Tam, V. H., & Leibovici, L. (2021). New β-lactam–β-lactamase inhibitor combinations. Clinical Microbiology Reviews, 34(1). https://doi.org/10.1128/CMR.00115-20
Aslan, A. T., Ezure, Y., Horcajada, J. P., Harris, P. N. A., & Paterson, D. L. (2023). In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review. In Frontiers in Medicine (Vol. 10). https://doi.org/10.3389/fmed.2023.1249030
Corcione, S., de Benedetto, I., Shbaklo, N., Torsello, G., Lupia, T., Bianco, G., Cavallo, R., Brazzi, L., Montrucchio, G., & de Rosa, F. G. (2023). Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with? International Journal of Molecular Sciences, 24(5). https://doi.org/10.3390/ijms24054767
Petrosillo, N., Taglietti, F., & Granata, G. (2019). Treatment options for colistin resistant klebsiella pneumoniae: Present and future. In Journal of Clinical Medicine (Vol. 8, Issue 7). https://doi.org/10.3390/jcm8070934
Zhang, F., Zhong, J., Ding, H., & Liao, G. (2021). Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant klebsiella pneumoniae infection after kidney transplantation. Infection and Drug Resistance, 14. https://doi.org/10.2147/IDR.S343505
Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R, Guo Y, Hu F. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev. 2023 Dec 20;36(4):e0000823. doi: 10.1128/cmr.00008-23. Epub 2023 Nov 8. PMID: 37937997; PMCID: PMC10732083.
Logan, L. K., & Weinstein, R. A. (2017). The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. Journal of Infectious Diseases, 215 https://doi.org/10.1093/infdis/jiw282
Chiotos, K., Hayes, M., Gerber, J. S., & Tamma, P. D. (2019). Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. In Journal of the Pediatric Infectious Diseases Society (Vol. 9, Issue 1). https://doi.org/10.1093/jpids/piz085
Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., Press, E. G., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016). Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clinical Infectious Diseases, 63(12). https://doi.org/10.1093/cid/ciw636
Giddins, M. J., Macesic, N., Annavajhala, M. K., Stump, S., Khan, S., McConville, T. H., Mehta, M., Gomez-Simmonds, A., & Uhlemanna, A. C. (2018). Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring klebsiella pneumoniae sequence type 307 isolates. Antimicrobial Agents and Chemotherapy, 62(3). https://doi.org/10.1128/AAC.02101-17
van Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., Kaye, K. S., Fowler, V. G., Paterson, D. L., Bonomo, R. A., & Evans, S. (2018). Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases, 66(2). https://doi.org/10.1093/cid/cix783
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. v., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017). Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrobial Agents and Chemotherapy, 61(8). https://doi.org/10.1128/AAC.00883-17
Zheng, G., Cai, J., Zhang, L., Chen, D., Wang, L., Qiu, Y., Deng, H., Bai, H., Bian, X., & He, J. (2022). Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study. Infectious Diseases and Therapy, 11(5). https://doi.org/10.1007/s40121-022-00682-0
Tumbarello, M., Trecarichi, E. M., Corona, A., de Rosa, F. G., Bassetti, M., Mussini, C., Menichetti, F., Viscoli, C., Campoli, C., Venditti, M., de Gasperi, A., Mularoni, A., Tascini, C., Parruti, G., Pallotto, C., Sica, S., Concia, E., Cultrera, R., de Pascale, G., … Viale, P. (2019). Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients with Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clinical Infectious Diseases, 68(3). https://doi.org/10.1093/cid/ciy492
Luterbach, C. L., Qiu, H., Hanafin, P. O., Sharma, R., Piscitelli, J., Lin, F. C., Ilomaki, J., Cober, E., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., Kaye, K. S., Nation, R. L., Bonomo, R. A., Landersdorfer, C. B., van Duin, D., & Rao, G. G. (2022). A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 66(10). https://doi.org/10.1128/aac.00591-22
Gu, J., Xu, J., Zuo, T. ting, & Chen, Y. bin. (2021). Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections. Journal of Global Antimicrobial Resistance, 26. https://doi.org/10.1016/j.jgar.2021.04.022
Chegini, Z., Khoshbayan, A., Vesal, S., Moradabadi, A., Hashemi, A., & Shariati, A. (2021). Bacteriophage therapy for inhibition of multi drug‐resistant uropathogenic bacteria: a narrative review. In Annals of Clinical Microbiology and Antimicrobials (Vol. 20, Issue 1). https://doi.org/10.1186/s12941-021-00433-y
Holloway, A. J., Yu, J. J., Arulanandam, B. P., Hoskinson, S. M., & Eaves-Pyles, T. (2018). Cystatins 9 and C as a novel immunotherapy treatment that protects against multidrug-resistant New Delhi metallo-beta-lactamase-1-producing klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 62(3). https://doi.org/10.1128/AAC.01900-17
Johnke, J., Fraune, S., Bosch, T. C. G., Hentschel, U., & Schulenburg, H. (2020). Bdellovibrio and Like Organisms Are Predictors of Microbiome Diversity in Distinct Host Groups. Microbial Ecology, 79(1). https://doi.org/10.1007/s00248-019-01395-7
Boucher HW, Talbot GH, Benjamin DK, Jr., et al. 10 × '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America(Vol. 35, Issue 8). https://doi.org/10.1002/phar.1622
Tacconelli, E., & Magrini, N. (2017). Global Priority List Of Antibiotic-Resistant Bacteria To Guide Research, Discovery, And Development Of New Antibiotics. World Health Organization, 43(148)
Zheng, G., Zhang, J., Wang, B., Cai, J., Wang, L., Hou, K., Zhang, Y., Zhang, L., Yang, Z., He, J., & Bian, X. (2021). Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study. Infectious Diseases and Therapy, 10(3). https://doi.org/10.1007/s40121-021-00479-7
Pragasam, A. K., Veeraraghavan, B., Shankar, B., Bakthavatchalam, Y., Mathuram, A., George, B., Chacko, B., Korula, P., & Anandan, S. (2019). Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from in vitro study. Indian Journal of Medical Microbiology, 37(1). https://doi.org/10.4103/ijmm.IJMM_19_189
Temkin, E., Torre-Cisneros, J., Beovic, B., Benito, N., Giannella, M., Gilarranz, R., Jeremiah, C., Loeches, B., MacHuca, I., Jiménez-Martín, M. J., Martínez, J. A., Mora-Rillo, M., Navas, E., Osthoff, M., Pozo, J. C., Ramos, J. C. R., Rodriguez, M., Sánchez-García, M., Viale, P., … Carmeli, Y. (2017). Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrobial Agents and Chemotherapy, 61(2). https://doi.org/10.1128/AAC.01964-16
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Patrycja Paschke, Igor Miczek, Maria Sambura, Sara Rosołowska-Żak, Julia Pałuchowska, Anna Szymkowicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 211
Number of citations: 0
